tweetindex
IT

BioNTech SE

@BioNTech_Group · Mainz, Germany · joined 09 Nov 2018

Our vision: Harnessing the immune system’s power to turn science into survival. Data Privacy: https://t.co/ZHMXceTxRG Imprint: https://t.co/VNRPNHg7b0

79 286Followers
163Following
317Posts total
17.6KViews on collected posts

Ultimi post

Lung cancer is not one disease. Following #WCLC26, Dr.@StephenVLiu reflects on the complexity of lung cancer, how our understanding has evolved and why different strategies need to be explored to address the needs that remain. Watch 👇 #LungCancer #CancerResearch https://t.co/o
1:27
2K views · 8 likes · 1 reposts · 0 replies Open on X →
📢 Oncology news in 2L+ sqNSCLC: We presented the first median overall survival data from the PRESERVE-003 Phase 3 trial for a chemotherapy-free CTLA-4-targeting immunotherapy in 2L+ squamous non-small cell lung cancer. 🔗 Learn more: https://t.co/pRJObzsXtr #LungCancer #WCLC26 ht
2.9K views · 29 likes · 3 reposts · 1 replies Open on X →
https://t.co/C5Z66j4xwv
604 views · 5 likes · 0 reposts · 0 replies Open on X →
https://t.co/lhMMzeVL5d
705 views · 5 likes · 0 reposts · 1 replies Open on X →
https://t.co/T7bbFZB7pe
806 views · 5 likes · 0 reposts · 1 replies Open on X →
We are excited to share new clinical data from our diversified lung cancer pipeline, including the first combination data for any PD-(L)1xVEGF bispecific plus a B7H3 ADC in lung cancer. 🔗 Learn more: https://t.co/wi0RxnC3Cb #LungCancer #Oncology #WCLC26 #BioNTech https://t.co/P
4.3K views · 47 likes · 4 reposts · 6 replies Open on X →
Photo copyright Guido Oelkers: Sobi - Swedish Orphan Biovitrum AB (publ), 2026 https://t.co/EIREWKX9yp
866 views · 3 likes · 0 reposts · 0 replies Open on X →
📢 𝗤𝟮 𝟮𝟬𝟮𝟲 𝗲𝗮𝗿𝗻𝗶𝗻𝗴𝘀 𝗿𝗲𝘀𝘂𝗹𝘁𝘀 𝗮𝗻𝗱 𝗰𝗼𝗺𝗽𝗮𝗻𝘆 𝘂𝗽𝗱𝗮𝘁𝗲 𝗟𝗶𝗻𝗸 𝘁𝗼 𝗽𝗿𝗲𝘀𝘀 𝗿𝗲𝗹𝗲𝗮𝘀𝗲 𝗮𝗻𝗱 𝗳𝗼𝗿𝘄𝗮𝗿𝗱-𝗹𝗼𝗼𝗸𝗶𝗻𝗴 𝘀𝘁𝗮𝘁𝗲𝗺𝗲𝗻𝘁𝘀: https://t.co/Vuzq8yVvGD https://t.co/FHQYTo1Z4T
3K views · 12 likes · 1 reposts · 1 replies Open on X →
We are building for the many within lung cancer. Through 16+ clinical trials, we are pursuing innovative therapeutic approaches across subtypes and biomarkers to advance progress where patients still need more. Explore the many: https://t.co/Zyfprgjp9U #WorldLungCancerDay http
2.5K views · 9 likes · 1 reposts · 0 replies Open on X →

Rispetto ad account della stessa dimensione

9 post degli ultimi 90 giorni, accanto alla fascia di 10K–100K follower. sotto i pari sia per copertura sia per interazione.

Visualizzazioni mediane2 025questo account940mediana per 10K–100K
Copertura, %2.55%questo account3.45%mediana per 10K–100K
Interazione, %0.74%questo account1.55%mediana per 10K–100K
MetricaQuesto accountMediana per 10K–100KRapporto
Visualizzazioni mediane per post2 0259402.15×
Copertura (visualizzazioni ÷ follower)2.55%3.45%0.74×
Tasso di interazione0.74%1.55%0.48×

Altri account di questa fascia →   Confronta con un altro account →   Come sono costruiti questi parametri →

Growth & engagement

How the posts we collected actually performed: views and reaction rate post by post, what the audience did with them, and where the follower count goes.

Views per post

2.5K1 Aug
3K4 Aug
866
4.3K20 Aug
806
705
604
2.9K14 Sep
2K16 Sep

Last 9 collected posts, oldest on the left. The scale is logarithmic: one post can outrun the rest a hundred times over.

Engagement rate per post

0.41%1 Aug
0.47%4 Aug
0.35%
1.38%20 Aug
0.74%
0.85%
0.83%
1.13%14 Sep
0.44%16 Sep

Reactions — likes, reposts, replies and quotes — divided by views. Median for 10K–100K accounts is 1.55%.

What the audience does

Likes78.8%123 in total
Reposts6.4%10 in total
Replies6.4%10 in total
Quotes1.3%2 in total
Bookmarks7.1%11 in total

Share of every reaction we collected for this account. Replies mean argument, reposts mean endorsement, bookmarks mean the post was worth keeping.

The follower curve appears once this account has two daily snapshots — we take one a day, and this one is on its first.

Account simili